Cargando…
Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management
Chordoid meningioma is a morphological variant of meningioma designated as WHO grade 2. However, the recurrence rates varied widely in different case series, and to date, a unifying molecular genetic signature has not been identified. Among 1897 meningiomas resected at our institution, we identified...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020042/ https://www.ncbi.nlm.nih.gov/pubmed/35440040 http://dx.doi.org/10.1186/s40478-022-01362-3 |
_version_ | 1784689443887644672 |
---|---|
author | Daoud, Elena V. Zhu, Kelsey Mickey, Bruce Mohamed, Hussein Wen, Mandisa Delorenzo, Michael Tran, Ivy Serrano, Jonathan Hatanpaa, Kimmo J. Raisanen, Jack M. Snuderl, Matija Cai, Chunyu |
author_facet | Daoud, Elena V. Zhu, Kelsey Mickey, Bruce Mohamed, Hussein Wen, Mandisa Delorenzo, Michael Tran, Ivy Serrano, Jonathan Hatanpaa, Kimmo J. Raisanen, Jack M. Snuderl, Matija Cai, Chunyu |
author_sort | Daoud, Elena V. |
collection | PubMed |
description | Chordoid meningioma is a morphological variant of meningioma designated as WHO grade 2. However, the recurrence rates varied widely in different case series, and to date, a unifying molecular genetic signature has not been identified. Among 1897 meningiomas resected at our institution, we identified 12 primary chordoid meningiomas from 12 patients. Histologically, all 12 cases had predominant (> 50%) chordoid morphology. Ten were otherwise grade 1, and two were also atypical. We performed DNA global methylation profile, copy number variation analysis, and targeted next-generation sequencing on 11 chordoid meningiomas, and compared to those of 51 non-chordoid, mostly high grade meningiomas. The chordoid meningiomas demonstrated a unique methylation profile in tSNE, UMAP, and hierarchical heatmap clustering analyses of the most differentially methylated CpGs. The most common copy number variation in chordoid meningioma was loss of 1p (7/11, 64%). Three chordoid meningiomas had 2p loss, which was significantly higher than the non-chordoid control cohort (27% vs 7.2%, p = 0.035). 22q loss was only seen in the two cases with additional atypical histological features. Chordoid meningiomas were enriched in mutations in chromatin remodeling genes EP400 (8/11,73%) KMT2C (4/11, 36%) and KMT2D (4/11, 36%), and showed low or absent NF2, TERT, SMO, and AKT1 mutations. Prognosis wise, only one case recurred. This case had atypical histology and high-grade molecular features including truncating NF2 mutation, 1p, 8p, 10, 14, 22q loss, and homozygous deletion of CDKN2A/B. Progression free survival of chordoid, otherwise grade 1 meningioma was comparable to non-chordoid WHO grade 1 meningioma (p = 0.75), and significantly better than chordoid WHO grade 2 meningioma (p = 0.019). Conclusion: the chordoid histology alone may not justify a universal WHO grade 2 designation. Screening for additional atypical histological or molecular genetic features is recommended. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01362-3. |
format | Online Article Text |
id | pubmed-9020042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90200422022-04-21 Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management Daoud, Elena V. Zhu, Kelsey Mickey, Bruce Mohamed, Hussein Wen, Mandisa Delorenzo, Michael Tran, Ivy Serrano, Jonathan Hatanpaa, Kimmo J. Raisanen, Jack M. Snuderl, Matija Cai, Chunyu Acta Neuropathol Commun Research Chordoid meningioma is a morphological variant of meningioma designated as WHO grade 2. However, the recurrence rates varied widely in different case series, and to date, a unifying molecular genetic signature has not been identified. Among 1897 meningiomas resected at our institution, we identified 12 primary chordoid meningiomas from 12 patients. Histologically, all 12 cases had predominant (> 50%) chordoid morphology. Ten were otherwise grade 1, and two were also atypical. We performed DNA global methylation profile, copy number variation analysis, and targeted next-generation sequencing on 11 chordoid meningiomas, and compared to those of 51 non-chordoid, mostly high grade meningiomas. The chordoid meningiomas demonstrated a unique methylation profile in tSNE, UMAP, and hierarchical heatmap clustering analyses of the most differentially methylated CpGs. The most common copy number variation in chordoid meningioma was loss of 1p (7/11, 64%). Three chordoid meningiomas had 2p loss, which was significantly higher than the non-chordoid control cohort (27% vs 7.2%, p = 0.035). 22q loss was only seen in the two cases with additional atypical histological features. Chordoid meningiomas were enriched in mutations in chromatin remodeling genes EP400 (8/11,73%) KMT2C (4/11, 36%) and KMT2D (4/11, 36%), and showed low or absent NF2, TERT, SMO, and AKT1 mutations. Prognosis wise, only one case recurred. This case had atypical histology and high-grade molecular features including truncating NF2 mutation, 1p, 8p, 10, 14, 22q loss, and homozygous deletion of CDKN2A/B. Progression free survival of chordoid, otherwise grade 1 meningioma was comparable to non-chordoid WHO grade 1 meningioma (p = 0.75), and significantly better than chordoid WHO grade 2 meningioma (p = 0.019). Conclusion: the chordoid histology alone may not justify a universal WHO grade 2 designation. Screening for additional atypical histological or molecular genetic features is recommended. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01362-3. BioMed Central 2022-04-19 /pmc/articles/PMC9020042/ /pubmed/35440040 http://dx.doi.org/10.1186/s40478-022-01362-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Daoud, Elena V. Zhu, Kelsey Mickey, Bruce Mohamed, Hussein Wen, Mandisa Delorenzo, Michael Tran, Ivy Serrano, Jonathan Hatanpaa, Kimmo J. Raisanen, Jack M. Snuderl, Matija Cai, Chunyu Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title | Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title_full | Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title_fullStr | Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title_full_unstemmed | Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title_short | Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
title_sort | epigenetic and genomic profiling of chordoid meningioma: implications for clinical management |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020042/ https://www.ncbi.nlm.nih.gov/pubmed/35440040 http://dx.doi.org/10.1186/s40478-022-01362-3 |
work_keys_str_mv | AT daoudelenav epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT zhukelsey epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT mickeybruce epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT mohamedhussein epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT wenmandisa epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT delorenzomichael epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT tranivy epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT serranojonathan epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT hatanpaakimmoj epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT raisanenjackm epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT snuderlmatija epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement AT caichunyu epigeneticandgenomicprofilingofchordoidmeningiomaimplicationsforclinicalmanagement |